The basic net loss per share for the first quarter of Fiscal 2008 was ($0.06), compared to a net loss per share of ($0.07) recorded in the same period last year.
Annual Meeting Highlights
At the Company's Annual and Special Meeting of Shareholders yesterday afternoon in Toronto, Ontario, the Company provided an update on its Phase III clinical program with Urocidin in bladder cancer and its E. coli O157:H7 vaccine program. In the first Phase III trial involving refractory bladder cancer patients treated with Urocidin, it was reported that the Data Safety Monitoring Committee is satisfied with the progress of the trial and that recruitment of the 105 patients should be completed by mid-2008. With its E. coli O157:H7 vaccine, Bioniche is in the process of building industry awareness about this bacterium and in support of sales to high profile early adopters.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 195 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit http://www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but ar
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved